doi: 10.1001/jama.297.3.252.
MRI contrast agents may pose risk for patients with kidney disease
- PMID: 17227968
- DOI: 10.1001/jama.297.3.252
Item in Clipboard
MRI contrast agents may pose risk for patients with kidney disease
JAMA.
.
No abstract available
Similar articles
-
[Nephrogenic systemic fibrosis].G Ital Nefrol. 2008 Jan-Feb;25(1):14-20. G Ital Nefrol. 2008. PMID: 18264914 Review. Italian.
-
Extracellular Gd-CA: differences in prevalence of NSF.Eur J Radiol. 2008 May;66(2):180-3. doi: 10.1016/j.ejrad.2008.01.024. Epub 2008 Mar 14. Eur J Radiol. 2008. PMID: 18342468 Review.
-
How should nephrologists approach gadolinium-based contrast imaging in patients with kidney disease?Clin J Am Soc Nephrol. 2008 May;3(3):649-51. doi: 10.2215/CJN.00670208. Epub 2008 Apr 2. Clin J Am Soc Nephrol. 2008. PMID: 18385396 No abstract available.
-
[Gadolinium: a true problem for the nephrologists?].G Ital Nefrol. 2008 Jan-Feb;25(1):3-4. G Ital Nefrol. 2008. PMID: 18264906 Italian. No abstract available.
-
Gadolinium contrast may be risky in kidney disease.BMJ. 2007 Jun 30;334(7608):1335-6. doi: 10.1136/bmj.39254.924641.1F. BMJ. 2007. PMID: 17599982 Free PMC article. No abstract available.
Cited by
-
Contrast-enhanced cardiovascular magnetic resonance in the hyperacute phase of ST-elevation myocardial infarction.Int J Cardiovasc Imaging. 2009 Jun;25(5):519-27. doi: 10.1007/s10554-009-9451-4. Epub 2009 Mar 15. Int J Cardiovasc Imaging. 2009. PMID: 19288259
-
Smart Biomimetic Nanozymes for Precise Molecular Imaging: Application and Challenges.Pharmaceuticals (Basel). 2023 Feb 7;16(2):249. doi: 10.3390/ph16020249. Pharmaceuticals (Basel). 2023. PMID: 37259396 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
